Target Price | $14.28 |
Price | $3.56 |
Potential |
301.12%
register free of charge
|
Number of Estimates | 13 |
13 Analysts have issued a price target Relay Therapeutics Inc 2026 .
The average Relay Therapeutics Inc target price is $14.28.
This is
301.12%
register free of charge
$30.45
755.34%
register free of charge
$4.04
13.48%
register free of charge
|
|
A rating was issued by 19 analysts: 16 Analysts recommend Relay Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Relay Therapeutics Inc stock has an average upside potential 2026 of
301.12%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 10.01 | 11.77 |
60.82% | 17.55% | |
EBITDA Margin | -3,666.33% | -3,281.35% |
154.74% | 10.50% | |
Net Margin | -3,373.73% | -2,760.21% |
152.07% | 18.19% |
14 Analysts have issued a sales forecast Relay Therapeutics Inc 2025 . The average Relay Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Relay Therapeutics Inc EBITDA forecast 2025. The average Relay Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Relay Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Relay Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.36 | -1.91 |
15.41% | 19.07% | |
P/E | negative | |
EV/Sales | negative |
14 Analysts have issued a Relay Therapeutics Inc forecast for earnings per share. The average Relay Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Relay Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
Analyst Rating | Date |
---|---|
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 14 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Dec 12 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.